Robert Coutts
Director of Finance/CFO bij ACHILLES THERAPEUTICS PLC
Vermogen: 238 039 $ op 31-03-2024
Oorsprong van het eerstegraads netwerk van Robert Coutts
Entiteit | Type entiteit | Industrie | |
---|---|---|---|
Public Company | Pharmaceuticals: Major | 17 | |
Mutual Fd-Closed End | Investment Trusts/Mutual Funds | 10 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Robert Coutts via zijn persoonlijke netwerk
Onderneming | Sector | Gelieerde personen | Hoofdpost |
---|---|---|---|
Bausch & Lomb, Inc.
Bausch & Lomb, Inc. Medical SpecialtiesHealth Technology Bausch & Lomb, Inc. develops, manufactures, and markets eye health products. It offers over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care, ophthalmic surgical devices, and instruments. The company was founded by John Jacob Bausch and Henry Lomb in 1853 and is headquartered in Rochester, NY. | Medical Specialties | Chief Tech/Sci/R&D Officer | |
MERCK & CO., INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
PFIZER, INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
ALTRIA GROUP, INC. | Tobacco | Director/Board Member | |
ALEXION PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director of Finance/CFO Chief Operating Officer | |
MERCK KGAA | Pharmaceuticals: Major | Corporate Officer/Principal | |
Novartis Corp.
Novartis Corp. Pharmaceuticals: MajorHealth Technology Novartis Corp. manufactures pharmaceuticals, vaccines, consumer health, generics, eye care and animal health products. It manufactures drugs for oncology, hypertension, diabetes, cancer and cardiovascular diseases. The company was founded on November 15, 1996 and is headquartered in New York, NY. | Pharmaceuticals: Major | Corporate Officer/Principal | |
ADMA BIOLOGICS, INC. | Biotechnology | Director/Board Member | |
AFFIMED N.V. | Biotechnology | Director/Board Member | |
GSK PLC | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
BIOTEST AG | Pharmaceuticals: Other | Chairman | |
University of Oxford | College/University | Graduate Degree Doctorate Degree Doctorate Degree | |
University of Cambridge | College/University | Undergraduate Degree Doctorate Degree Graduate Degree Masters Business Admin Graduate Degree Undergraduate Degree | |
ATON | Pharmaceuticals: Major | Director/Board Member | |
The Johns Hopkins University | College/University | Undergraduate Degree | |
University College London | College/University | Founder Corporate Officer/Principal Corporate Officer/Principal Doctorate Degree Doctorate Degree | |
Ruprecht-Karls-Universität Heidelberg | College/University | Undergraduate Degree | |
Ludwig-Maximilians-Universität München | College/University | Undergraduate Degree | |
Culross Global Management Ltd.
Culross Global Management Ltd. Investment ManagersFinance Culross Global Management Ltd. (Culross Global) is an independent asset management firm headquartered in London, UK. The firm was founded by Nigel G. Blanshard in 1992. Culross Global serves a diversified investor base of institutional and qualifying high net worth investors, for whom they manage a range of funds, bespoke portfolios and wealth management solutions with tailored risk and return objectives. | Investment Managers | Analyst-Equity | |
Symphogen A/S
Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | Pharmaceuticals: Major | Chairman | |
Oxford Technology Enterprise Capital Fund LP
Oxford Technology Enterprise Capital Fund LP Investment ManagersFinance Oxford Technology Enterprise Capital Fund LP seeks investment opportunities in technology companies located in the UK. The fund provides financing for seed and early stage capital requirements with an investment size of £0.1 - £2 million. It also considers investments in follow-on rounds. | Investment Managers | Director/Board Member | |
EPIZYME, INC. | Biotechnology | Chief Tech/Sci/R&D Officer | |
Think Tank, Inc.
Think Tank, Inc. Specialty StoresRetail Trade Think Tank, Inc. is an American company that retails jewelry. The CEO of the private company is Michael A. Casalini. | Specialty Stores | Director/Board Member | |
Santia Holdco Ltd.
Santia Holdco Ltd. Financial ConglomeratesFinance Part of Ligtas Consultancy & Training Ltd., Santia Holdco Ltd. operates as a holding British company. The private company is based in Nantgarw, UK. Santia Holdco was founded in 2011. | Financial Conglomerates | Director/Board Member | |
BETTER CAPITAL PCC 2009 ORD | Investment Managers | Director/Board Member | |
Vivat Direct Ltd.
Vivat Direct Ltd. Publishing: Books/MagazinesConsumer Services Vivat Direct Ltd. provides publishing services. It offers periodicals on jewelry, gifts, health and beauty, pet care, money insurance, and travel. The company was founded by DeWitt Wallace in 1922 and is headquartered in London, the United Kingdom. | Publishing: Books/Magazines | Director/Board Member | |
The Syncona Foundation | Investment Trusts/Mutual Funds | Director/Board Member Director/Board Member Director/Board Member | |
Johns Hopkins Bloomberg School of Public Health | College/University | Graduate Degree | |
Syncona Partners LLP
Syncona Partners LLP Investment ManagersFinance Syncona Partners LLP (Syncona Partners) is a venture capital subsidiary of Syncona Investment Management Ltd. founded in 2012 by Martin Murphy. The firm is headquartered in London, United Kingdom. | Investment Managers | Private Equity Investor Director/Board Member Private Equity Investor | |
The Johns Hopkins University School of Medicine | College/University | Doctorate Degree | |
The Spicers-Officeteam Group Ltd.
The Spicers-Officeteam Group Ltd. Wholesale DistributorsDistribution Services The Spicers-Officeteam Group Ltd. engages in manufacture and supply of electronic office products. The company is headquartered in Croydon, the United Kingdom. | Wholesale Distributors | Director/Board Member | |
EYENOVIA, INC. | Pharmaceuticals: Major | Director/Board Member | |
RAPT THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member | |
Achilles Therapeutics UK Ltd.
Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Achilles Therapeutics Ltd. operates as a biopharmaceutical company. The firm develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer. It uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. The company was founded by Karl Peggs, Mark Lowdell, Charles Swanton and Sergio Quezada in May 2016 and is headquartered in London, the United Kingdom. | Biotechnology | Director/Board Member Chairman Director/Board Member Chief Executive Officer Founder Founder Founder Director/Board Member Founder | |
Syncona Investment Management Ltd.
Syncona Investment Management Ltd. Investment ManagersFinance Syncona Investment Management Ltd. (Syncona) is the asset management subsidiary of Syncona Ltd. in Great Britain. Headquartered in London, the firm was co-founded by Martin Murphy alongside The Wellcome Trust. Syncona is focused on founding, building and funding a portfolio of global leaders in life science. | Investment Managers | Chairman Head-Equity Investments | |
Shoreham Shop LLP | Director/Board Member | ||
Verdi Semiconductor Ltd. | Director/Board Member | ||
Vivat Finance Ltd. | Director/Board Member | ||
ODYSSEAN INVESTMENT TRUST PLC | Investment Trusts/Mutual Funds | Director/Board Member | |
Hyde Capital Partners Ltd. | Founder | ||
Affimed GmbH
Affimed GmbH Miscellaneous Commercial ServicesCommercial Services Part of Affimed NV, Affimed GmbH is a clinical leader in innate immuno-oncology. The private company, based in Heidelberg, Germany, develops proprietary cancer-targeting bispecific antibodies that activate the innate immune system to kill tumor cells. Affimed leads clinical development of innate cell engagers for solid/hematologic tumors as monotherapy, in combination with NK cells or with checkpoint inhibitors. Adolf Hoess has been the CEO of the German company since 2010. | Miscellaneous Commercial Services | Director/Board Member |
Statistieken
Internationaal
Verenigd Koninkrijk | 21 |
Verenigde Staten | 17 |
Duitsland | 10 |
Frankrijk | 2 |
Denemarken | 2 |
Sectoraal
Health Technology | 20 |
Consumer Services | 10 |
Finance | 8 |
Commercial Services | 3 |
Miscellaneous | 3 |
Operationeel
Director/Board Member | 156 |
Chairman | 50 |
Corporate Officer/Principal | 43 |
Independent Dir/Board Member | 38 |
Founder | 20 |
Sterkste connecties
Insiders | |
---|---|
Jonathan P. Moulton | 76 |
Edwin Moses | 35 |
Nigel Keen | 19 |
Derek DiRocco | 17 |
Bernhard R. M. Ehmer | 16 |
Julie O'Neill | 16 |
Carsten Boess | 15 |
Colin C. Maltby | 15 |
Ellen Strahlman | 14 |
Mark Lowdell | 12 |
Peter Hames | 12 |
Martin Nicholas Caleb Thomas | 11 |
Iraj Ali | 10 |
Michael Giordano | 9 |
Charles Swanton | 7 |
- Beurs
- Insiders
- Robert Coutts
- Bedrijfsconnecties